Significant lack of urine-based biomarkers to replace cystoscopy for the surveillance of non-muscle invasive bladder cancer.
作者信息
Miyake Makito, Owari Takuya, Hori Shunta, Fujimoto Kiyohide
机构信息
Department of Urology, Nara Medical University, Kashihara, Nara, Japan.
出版信息
Transl Androl Urol. 2019 Jul;8(Suppl 3):S332-S334. doi: 10.21037/tau.2019.05.07.
Abstract
摘要
相似文献
1
Significant lack of urine-based biomarkers to replace cystoscopy for the surveillance of non-muscle invasive bladder cancer.用于非肌层浸润性膀胱癌监测的尿液生物标志物严重缺乏，无法替代膀胱镜检查。
Transl Androl Urol. 2019 Jul;8(Suppl 3):S332-S334. doi: 10.21037/tau.2019.05.07.
2
Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.非肌层浸润性膀胱癌的随访——国际膀胱癌网络建议
Urol Oncol. 2016 Oct;34(10):460-8. doi: 10.1016/j.urolonc.2016.05.028. Epub 2016 Jun 29.
3
Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer.用于非肌层浸润性膀胱癌早期检测和监测的尿液生物标志物。
Minerva Urol Nefrol. 2008 Dec;60(4):217-35.
4
The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer.荧光原位杂交检测在非肌层浸润性膀胱癌监测中的作用。
Can J Urol. 2010 Apr;17(2):5077-81.
5
Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.在低风险非肌层浸润性膀胱癌患者随访中用尿液标志物取代膀胱镜检查？——一项国际膀胱癌网络项目。
Urol Oncol. 2016 Oct;34(10):452-9. doi: 10.1016/j.urolonc.2016.06.001. Epub 2016 Jul 2.
6
Can urinary biomarkers replace cystoscopy?尿生物标志物能否替代膀胱镜检查？
World J Urol. 2019 Sep;37(9):1741-1749. doi: 10.1007/s00345-018-2505-2. Epub 2018 Oct 3.
7
Urine markers for detection and surveillance of non-muscle-invasive bladder cancer.尿液标志物在非肌层浸润性膀胱癌检测和监测中的应用。
Eur Urol. 2011 Sep;60(3):484-92. doi: 10.1016/j.eururo.2011.05.053. Epub 2011 Jun 12.
8
FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.在一项大型前瞻性多中心研究中，FGFR3、TERT和OTX1作为膀胱癌患者监测的尿液生物标志物组合
J Urol. 2017 Jun;197(6):1410-1418. doi: 10.1016/j.juro.2016.12.096. Epub 2016 Dec 31.
9
Use of urinary biomarkers for bladder cancer surveillance: patient perspectives.使用尿液生物标志物进行膀胱癌监测：患者视角
J Urol. 2007 Apr;177(4):1277-82; discussion 1282. doi: 10.1016/j.juro.2006.11.066.
10
Urinary markers in the everyday diagnosis of bladder cancer.膀胱癌日常诊断中的尿液标志物
Urologia. 2013 Sep-Dec;80(4):265-75. doi: 10.5301/urologia.5000041. Epub 2013 Nov 29.
引用本文的文献
1
Biomarker discovery and beyond for diagnosis of bladder diseases.用于膀胱疾病诊断的生物标志物发现及其他应用
Bladder (San Franc). 2020 Mar 24;7(1):e40. doi: 10.14440/bladder.2020.813. eCollection 2020.
2
MicroRNAs Which Can Prognosticate Aggressiveness of Bladder Cancer.可预测膀胱癌侵袭性的微小RNA
Cancers (Basel). 2019 Oct 14;11(10):1551. doi: 10.3390/cancers11101551.
本文引用的文献
1
Ability of a urine gene expression classifier to reduce the number of follow-up cystoscopies in bladder cancer patients.尿液基因表达分类器降低膀胱癌患者随访膀胱镜检查次数的能力。
Transl Res. 2019 Jun;208:73-84. doi: 10.1016/j.trsl.2019.02.003. Epub 2019 Feb 7.
2
Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma.用于尿路上皮癌诊断和监测的新兴生物标志物。
Res Rep Urol. 2018 Dec 14;10:251-261. doi: 10.2147/RRU.S173027. eCollection 2018.
3
Clinical evaluation of two consecutive UroVysion fluorescence in situ hybridization tests to detect intravesical recurrence of bladder cancer: a prospective blinded comparative study in Japan.日本前瞻性双盲对照研究：两次连续 UroVysion 荧光原位杂交检测膀胱癌膀胱内复发的临床评估。
Int J Clin Oncol. 2018 Dec;23(6):1140-1147. doi: 10.1007/s10147-018-1311-6. Epub 2018 Jul 3.
4
Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.用于排除复发性尿路上皮癌的非侵入性尿液检测的临床比较
Urol Oncol. 2017 Aug;35(8):531.e15-531.e22. doi: 10.1016/j.urolonc.2017.03.008. Epub 2017 Mar 31.
5
Active surveillance for nonmuscle invasive bladder cancer.主动监测非肌肉浸润性膀胱癌。
Investig Clin Urol. 2016 Jun;57 Suppl 1(Suppl 1):S4-S13. doi: 10.4111/icu.2016.57.S1.S4. Epub 2016 May 27.
6
Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study.用于膀胱癌非侵入性诊断的基因表达检测：一项前瞻性、盲法、国际多中心验证研究。
Eur J Cancer. 2016 Feb;54:131-138. doi: 10.1016/j.ejca.2015.11.003. Epub 2016 Jan 4.
7
Validation study of a noninvasive urine test for diagnosis and prognosis assessment of bladder cancer: evidence for improved models.用于膀胱癌诊断和预后评估的无创尿液检测的验证研究：改进模型的证据。
J Urol. 2014 Jan;191(1):261-9. doi: 10.1016/j.juro.2013.06.083. Epub 2013 Jul 2.
8
A multicolor fluorescence in situ hybridization assay: A monitoring tool in the surveillance of patients with a history of non-muscle-invasive urothelial cell carcinoma: A prospective study.多色荧光原位杂交检测：非肌层浸润性尿路上皮细胞癌患者监测工具——一项前瞻性研究。
Cancer Cytopathol. 2011 Dec 25;119(6):395-403. doi: 10.1002/cncy.20168. Epub 2011 Jun 29.
9
Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma.尿液基因表达谱诊断和评估膀胱癌侵袭性。
Clin Cancer Res. 2010 May 1;16(9):2624-33. doi: 10.1158/1078-0432.CCR-09-3373. Epub 2010 Apr 20.
10
Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer.尿脱落细胞中成纤维细胞生长因子受体 3 突变是一种有用的诊断标志物，也是非肌肉浸润性膀胱癌肿瘤复发的重要指标。
Cancer Sci. 2010 Jan;101(1):250-8. doi: 10.1111/j.1349-7006.2009.01334.x. Epub 2009 Sep 1.
Zotero 插件